Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

Drugs targeting the orthosteric, primary binding site of G protein–coupled receptors are the
most common therapeutics. Allosteric binding sites, elsewhere on the receptors, are less well-…

Conventional drug discovery efforts at the β 2 -adrenoceptor (β 2 AR) have led to the
development of ligands that bind almost exclusively to the receptor’s hormone-binding orthosteric …

Among β-blockers that are clinically prescribed for heart failure, carvedilol is a first-choice
agent with unique pharmacological properties. Carvedilol is distinct from other β-blockers in its …

Background The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular
(CV) events, and patients with pre-existing autoimmune disease are at increased CV risk. …

Background Type 2 myocardial infarction (T2MI) related to a supply/demand imbalance of
coronary blood flow is common and associated with poor prognosis. Coronary artery disease (…

Objectives Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related
adverse events (irAE) associated with immune checkpoint inhibitors (ICI). Skeletal …

Background Type 2 myocardial infarction (MI) results from coronary supply and demand
imbalance and has a poor prognosis. It is crucial to identify potential sex-based differences in …

BACKGROUND: Right ventricular (RV) dysfunction is associated with increased mortality
across a spectrum of cardiovascular diseases. The role of obesity in RV dysfunction and …

Background Immune checkpoint inhibitors (ICI) treat a broad range of cancers. In basic
studies, these checkpoints are also a critical regulator of atherosclerosis. However, there are …